Levodopa therapeutics for Parkinson's disease: new developments

被引：17

作者：

LeWitt, Peter A. ^{[1
,2
]}

机构：

[1] Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA

[2] Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA

来源：

PARKINSONISM & RELATED DISORDERS | 2009年 / 15卷

关键词：

Levodopa; Anti-parkinsonian therapy; New delivery system; L-DOPA; MOTOR FLUCTUATIONS; PHARMACOKINETICS; PROGRESSION; INITIATION; REPLACEMENT; DYSKINESIAS; CARBIDOPA; SYSTEM; TRIAL;

D O I：

10.1016/S1353-8020(09)70009-4

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Levodopa serves as the gold standard of anti-parkinsonian therapy and nearly every patient with Parkinson's disease eventually receives this drug. To improve upon levodopa therapy, several forms of treatment have been devised to augment its actions. and new delivery systems are under development. This new research offers promise for improving outcomes with this highly effective therapy. (c) 2008 Elsevier Ltd. All rights reserved.

引用

页码：S31 / S34

页数：4

共 39 条

[1] Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature [J].

Ahlskog, JE ;

Muenter, MD .

MOVEMENT DISORDERS, 2001, 16 (03) :448-458

[2]

Blindauer K, 2006, ARCH NEUROL-CHICAGO, V63, P210

[3] Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease [J].

Brooks, DJ ;

Frey, KA ;

Marek, KL ;

Oakes, D ;

Paty, D ;

Prentice, R ;

Shults, CW ;

Stoessl, AJ .

EXPERIMENTAL NEUROLOGY, 2003, 184 :S68-S79

[4]

Camp DM, 2000, J NEUROCHEM, V74, P1229

[5] 3,4-DIHYDROXYPHENYLALANINE AND 5-HYDROXYTRYPTOPHAN AS RESERPINE ANTAGONISTS [J].

CARLSSON, A ;

LINDQVIST, M ;

MAGNUSSON, T .

NATURE, 1957, 180 (4596) :1200-1200

[6] Restoration of the striatal dopamine synthesis for Parkinson's disease:: Viral vector-mediated enzyme replacement strategy [J].

Carlsson, Thomas ;

Bjorklund, Tomas ;

Kirik, Deniz .

CURRENT GENE THERAPY, 2007, 7 (02) :109-120

[7] AMOUNT AND DISTRIBUTION OF DIETARY-PROTEIN AFFECTS CLINICAL-RESPONSE TO LEVODOPA IN PARKINSONS-DISEASE [J].

CARTER, JH ;

NUTT, JG ;

WOODWARD, WR ;

HATCHER, LF ;

TROTMAN, TL .

NEUROLOGY, 1989, 39 (04) :552-556

[8] EFFECT OF SUPPLEMENTAL CARBIDOPA ON BIOAVAILABILITY OF L-DOPA [J].

CEDARBAUM, JM ;

KUTT, H ;

DHAR, AK ;

WATKINS, S ;

MCDOWELL, FH .

CLINICAL NEUROPHARMACOLOGY, 1986, 9 (02) :153-159

[9] EARLY INITIATION OF LEVODOPA TREATMENT DOES NOT PROMOTE THE DEVELOPMENT OF MOTOR RESPONSE FLUCTUATIONS, DYSKINESIAS, OR DEMENTIA IN PARKINSONS-DISEASE [J].

CEDARBAUM, JM ;

GANDY, SE ;

MCDOWELL, FH .

NEUROLOGY, 1991, 41 (05) :622-629

[10] Levodopa slows progression of Parkinson's disease. External validation by clinical trial simulation [J].

Chan, Phylinda L. S. ;

Nutt, John G. ;

Holford, Nicholas H. G. .

PHARMACEUTICAL RESEARCH, 2007, 24 (04) :791-802

← 1 2 3 4 →